Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 26, 2022

Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Carcinoma

JAMA Oncology

 

Additional Info

JAMA Oncology
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)
JAMA Oncol 2022 Apr 14;[EPub Ahead of Print], G Procopio, P Sepe, M Claps, S Buti, M Colecchia, P Giannatempo, V Guadalupi, L Mariani, L Lalli, G Fucà, F de Braud, E Verzoni

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.


Further Reading